From pathogenesis to therapy - Perspective on treatment strategies in fibrotic diseases

Pharmacological Research

Volumn 100, Issue , 2015, Pages 93-100

  Ramming, Andreas ^a   Dees, Clara ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Fibrosis

Indexed keywords

BETA CATENIN; MORPHOGEN; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN; CYTOKINE;

ADAPTIVE IMMUNITY; ARTICLE; BLOOD VESSEL INJURY; CYTOKINE RELEASE; EPIGENETICS; FIBROGENESIS; FIBROSIS; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TH17 CELL; VASCULARIZATION; ANIMAL; DRUG EFFECTS; ENDOTHELIUM; EXTRACELLULAR MATRIX; FIBROBLAST; INFLAMMATION; METABOLISM; PATHOLOGY; SKIN;

ANIMALS; CYTOKINES; ENDOTHELIUM; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; INFLAMMATION; SKIN;

EID: 84939237107     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.06.012     Document Type: Article

References (102)

1. T.A. Wynn, and T.R. Ramalingam Mechanisms of fibrosis: therapeutic translation for fibrotic disease Nat. Med. 18 2012 1028 1040
2. T.A. Wynn Cellular and molecular mechanisms of fibrosis J. Pathol. 214 2008 199 210
3. A. Gabrielli, E.V. Avvedimento, and T. Krieg Scleroderma N. Engl. J. Med. 360 2009 1989 2003
4. B. Hinz, S.H. Phan, V.J. Thannickal, M. Prunotto, A. Desmouliere, J. Varga, O. De Wever, M. Mareel, and G. Gabbiani Recent developments in myofibroblast biology: paradigms for connective tissue remodeling Am. J. Pathol. 180 2012 1340 1355
5. J. Varga, and D. Abraham Systemic sclerosis: a prototypic multisystem fibrotic disorder J. Clin. Invest. 117 2007 557 567
6. G.P. Rodnan, R.L. Myerowitz, and G.O. Justh Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon Medicine (Baltimore) 59 1980 393 408
7. C. Beyer, G. Schett, O. Distler, and J.H. Distler Animal models of systemic sclerosis: prospects and limitations Arthritis Rheum. 62 2010 2831 2844
8. B. Maurer, N. Busch, A. Jungel, M. Pileckyte, R.E. Gay, B.A. Michel, G. Schett, S. Gay, J. Distler, and O. Distler Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis Circulation 120 2009 2367 2376
9. K. Yamane, T. Miyauchi, N. Suzuki, T. Yuhara, T. Akama, H. Suzuki, and H. Kashiwagi Significance of plasma endothelin-1 levels in patients with systemic sclerosis J. Rheumatol. 19 1992 1566 1571
10. D. Lagares, R.A. Garcia-Fernandez, C.L. Jimenez, N. Magan-Marchal, O. Busnadiego, S. Lamas, and F. Rodriguez-Pascual Endothelin 1 contributes to the effect of transforming growth factor beta1 on wound repair and skin fibrosis Arthritis Rheum. 62 2010 878 889
11. S. Schroll, M. Arzt, D. Sebah, M. Nuchterlein, F. Blumberg, and M. Pfeifer Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan Respir. Physiol. Neurobiol. 170 2010 32 36
12. S.E. Mutsaers, R.P. Marshall, N.R. Goldsack, G.J. Laurent, and R.J. McAnulty Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats Pulm. Pharmacol. Ther. 11 1998 221 225
13. J.R. Seibold, C.P. Denton, D.E. Furst, L. Guillevin, L.J. Rubin, A. Wells, M. Matucci Cerinic, G. Riemekasten, P. Emery, H. Chadha-Boreham, P. Charef, S. Roux, and C.M. Black Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis Arthritis Rheum. 62 2010 2101 2108
14. Y. Furuya, and M. Kuwana Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study J. Rheumatol. 38 2011 2186 2192
15. F.M. Wigley, R.A. Wise, J.R. Seibold, D.A. McCloskey, G. Kujala, T.A. Medsger Jr., V.D. Steen, J. Varga, S. Jimenez, M. Mayes, P.J. Clements, S.R. Weiner, J. Porter, M. Ellman, C. Wise, L.D. Kaufman, J. Williams, and W. Dole Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study Ann. Intern. Med. 120 1994 199 206
16. C. Dees, C. Beyer, A. Distler, A. Soare, Y. Zhang, K. Palumbo-Zerr, O. Distler, G. Schett, P. Sandner, and J.H. Distler Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies Ann. Rheum. Dis. 2015 1621 1625
17. C. Dees, A. Akhmetshina, P. Zerr, N. Reich, K. Palumbo, A. Horn, A. Jungel, C. Beyer, G. Kronke, J. Zwerina, R. Reiter, N. Alenina, L. Maroteaux, S. Gay, G. Schett, O. Distler, and J.H. Distler Platelet-derived serotonin links vascular disease and tissue fibrosis J. Exp. Med. 208 2011 961 972
18. N.A. Hernandez-Rodriguez, A.D. Cambrey, N.K. Harrison, R.C. Chambers, A.J. Gray, A.M. Southcott, R.M. duBois, C.M. Black, M.F. Scully, R.J. McAnulty, and et al. Role of thrombin in pulmonary fibrosis Lancet 346 1995 1071 1073
19. M.L. Biondi, B. Marasini, E. Bianchi, and A. Agostoni Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon Int. J. Cardiol. 19 1988 335 339
20. S.S. Baroni, M. Santillo, F. Bevilacqua, M. Luchetti, T. Spadoni, M. Mancini, P. Fraticelli, P. Sambo, A. Funaro, A. Kazlauskas, E.V. Avvedimento, and A. Gabrielli Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis N. Engl. J. Med. 354 2006 2667 2676
21. S. Barrientos, O. Stojadinovic, M.S. Golinko, H. Brem, and M. Tomic-Canic Growth factors and cytokines in wound healing Wound Repair Regen. 16 2008 585 601
22. J. Pope, D. McBain, L. Petrlich, S. Watson, L. Vanderhoek, F. de Leon, S. Seney, and K. Summers Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center Arthritis Rheum. 63 2011 3547 3551
23. M. Manetti, S. Guiducci, E. Romano, C. Ceccarelli, S. Bellando-Randone, M.L. Conforti, L. Ibba-Manneschi, and M. Matucci-Cerinic Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis Circ. Res. 109 2011 e14 e26
24. B. Maurer, A. Distler, Y.A. Suliman, R.E. Gay, B.A. Michel, S. Gay, J.H. Distler, and O. Distler Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis Ann. Rheum. Dis. 73 2014 1880 1887
25. J. Huang, C. Beyer, K. Palumbo-Zerr, Y. Zhang, A. Ramming, A. Distler, K. Gelse, O. Distler, G. Schett, L. Wollin, and J.H. Distler Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis Ann. Rheum. Dis. 2015 10.1136/annrheumdis-2014-207109
26. F. Hilberg, G.J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, U. Tontsch-Grunt, P. Garin-Chesa, G. Bader, A. Zoephel, J. Quant, A. Heckel, and W.J. Rettig BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res. 68 2008 4774 4782
27. W.A. Wuyts, K.M. Antoniou, K. Borensztajn, U. Costabel, V. Cottin, B. Crestani, J.C. Grutters, T.M. Maher, V. Poletti, L. Richeldi, C. Vancheri, and A.U. Wells Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir. Med. 2 2014 933 942
28. P.L. McCormack Nintedanib: first global approval Drugs 75 2015 129 139
29. C. Beyer, N. Reich, S.C. Schindler, A. Akhmetshina, C. Dees, M. Tomcik, C. Hirth-Dietrich, G. von Degenfeld, P. Sandner, O. Distler, G. Schett, and J.H. Distler Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis Ann. Rheum. Dis. 71 2012 1019 1026
30. H.A. Ghofrani, N. Galie, F. Grimminger, E. Grunig, M. Humbert, Z.C. Jing, A.M. Keogh, D. Langleben, M.O. Kilama, A. Fritsch, D. Neuser, and L.J. Rubin Riociguat for the treatment of pulmonary arterial hypertension N. Engl. J. Med. 369 2013 330 340
31. N. Higashi-Kuwata, T. Makino, Y. Inoue, M. Takeya, and H. Ihn Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma Exp. Dermatol. 18 2009 727 729
32. C. Jakubzick, E.S. Choi, B.H. Joshi, M.P. Keane, S.L. Kunkel, R.K. Puri, and C.M. Hogaboam Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells J. Immunol. 171 2003 2684 2693
33. M.G. Chiaramonte, D.D. Donaldson, A.W. Cheever, and T.A. Wynn An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response J. Clin. Invest. 104 1999 777 785
34. D. Li, R. Guabiraba, A.G. Besnard, M. Komai-Koma, M.S. Jabir, L. Zhang, G.J. Graham, M. Kurowska-Stolarska, F.Y. Liew, C. McSharry, and D. Xu IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice J. Allergy Clin. Immunol. 134 2014 1422-1432 e1411
35. T. McHedlidze, M. Waldner, S. Zopf, J. Walker, A.L. Rankin, M. Schuchmann, D. Voehringer, A.N. McKenzie, M.F. Neurath, S. Pflanz, and S. Wirtz Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis Immunity 39 2013 357 371
36. K. Yanaba, A. Yoshizaki, Y. Asano, T. Kadono, and S. Sato Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis Clin. Rheumatol. 30 2011 825 830
37. I.G. Luzina, P. Kopach, V. Lockatell, P.H. Kang, A. Nagarsekar, A.P. Burke, J.D. Hasday, N.W. Todd, and S.P. Atamas Interleukin-33 potentiates bleomycin-induced lung injury Am. J. Respir. Cell Mol. Biol. 49 2013 999 1008
38. E. Hams, M.E. Armstrong, J.L. Barlow, S.P. Saunders, C. Schwartz, G. Cooke, R.J. Fahy, T.B. Crotty, N. Hirani, R.J. Flynn, D. Voehringer, A.N. McKenzie, S.C. Donnelly, and P.G. Fallon IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis Proc. Natl. Acad. Sci. U. S. A. 111 2014 367 372
39. M.E. Truchetet, N.C. Brembilla, E. Montanari, P. Lonati, E. Raschi, S. Zeni, L. Fontao, P.L. Meroni, and C. Chizzolini Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement Arthritis Rheum. 65 2013 1347 1356
40. M.S. Wilson, S.K. Madala, T.R. Ramalingam, B.R. Gochuico, I.O. Rosas, A.W. Cheever, and T.A. Wynn Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent J. Exp. Med. 207 2010 535 552
41. D. Boveda-Ruiz, C.N. D'Alessandro-Gabazza, M. Toda, T. Takagi, M. Naito, Y. Matsushima, T. Matsumoto, T. Kobayashi, P. Gil-Bernabe, A.L. Chelakkot-Govindalayathil, Y. Miyake, A. Yasukawa, J. Morser, O. Taguchi, and E.C. Gabazza Differential role of regulatory T cells in early and late stages of pulmonary fibrosis Immunobiology 218 2013 245 254
42. L.H. Calabrese, and S. Rose-John IL-6 biology: implications for clinical targeting in rheumatic disease Nat. Rev. Rheumatol. 10 2014 720 727
43. M. Hasegawa, S. Sato, H. Ihn, and K. Takehara Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis Rheumatology (Oxford) 38 1999 612 617
44. S. Sato, M. Hasegawa, and K. Takehara Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis J. Dermatol. Sci. 27 2001 140 146
45. L.I. Sakkas, I.C. Chikanza, and C.D. Platsoucas Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis Nat. Clin. Pract. Rheumatol. 2 2006 679 685
46. D.J. Abraham, T. Krieg, J. Distler, and O. Distler Overview of pathogenesis of systemic sclerosis Rheumatology (Oxford) 48 Suppl. 3 2009 iii3 iii7
47. A.E. Koch, L.B. Kronfeld-Harrington, Z. Szekanecz, M.M. Cho, G.K. Haines, L.A. Harlow, R.M. Strieter, S.L. Kunkel, M.C. Massa, W.G. Barr, and et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease Pathobiology: J. Immunopathol. Mol. Cell. Biol. 61 1993 239 246
48. S. O'Reilly, T. Hugle, and J.M. van Laar T cells in systemic sclerosis: a reappraisal Rheumatology (Oxford) 51 2012 1540 1549
49. R. Lafyatis, C. O'Hara, C.A. Feghali-Bostwick, and E. Matteson B cell infiltration in systemic sclerosis-associated interstitial lung disease Arthritis Rheum. 56 2007 3167 3168
50. M.L. Whitfield, D.R. Finlay, J.I. Murray, O.G. Troyanskaya, J.T. Chi, A. Pergamenschikov, T.H. McCalmont, P.O. Brown, D. Botstein, and M.K. Connolly Systemic and cell type-specific gene expression patterns in scleroderma skin Proc. Natl. Acad. Sci. U. S. A. 100 2003 12319 12324
51. S. Jordan, J.H. Distler, B. Maurer, D. Huscher, J.M. van Laar, Y. Allanore, and O. Distler Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group Ann. Rheum. Dis. 74 2015 1188 1194
52. R. Lafyatis Transforming growth factor beta - at the centre of systemic sclerosis Nat. Rev. Rheumatol. 10 2014 706 719
53. C.P. Denton, P.A. Merkel, D.E. Furst, D. Khanna, P. Emery, V.M. Hsu, N. Silliman, J. Streisand, J. Powell, A. Akesson, J. Coppock, F. Hoogen, A. Herrick, M.D. Mayes, D. Veale, J. Haas, S. Ledbetter, J.H. Korn, C.M. Black, and J.R. Seibold Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192 Arthritis Rheum. 56 2007 323 333
54. C. Beyer, O. Distler, and J.H. Distler Innovative antifibrotic therapies in systemic sclerosis Curr. Opin. Rheumatol. 24 2012 274 280
55. M. Hasegawa, S. Sato, and K. Takehara Augmented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis Arch. Dermatol. Res. 296 2004 89 93
56. J.S. Munger, X. Huang, H. Kawakatsu, M.J. Griffiths, S.L. Dalton, J. Wu, J.F. Pittet, N. Kaminski, C. Garat, M.A. Matthay, D.B. Rifkin, and D. Sheppard The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis Cell 96 1999 319 328
57. N.C. Henderson, T.D. Arnold, Y. Katamura, M.M. Giacomini, J.D. Rodriguez, J.H. McCarty, A. Pellicoro, E. Raschperger, C. Betsholtz, P.G. Ruminski, D.W. Griggs, M.J. Prinsen, J.J. Maher, J.P. Iredale, A. Lacy-Hulbert, R.H. Adams, and D. Sheppard Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs Nat. Med. 19 2013 1617 1624
58. L. van Bon, A.J. Affandi, J. Broen, R.B. Christmann, R.J. Marijnissen, L. Stawski, G.A. Farina, G. Stifano, A.L. Mathes, M. Cossu, M. York, C. Collins, M. Wenink, R. Huijbens, R. Hesselstrand, T. Saxne, M. DiMarzio, D. Wuttge, S.K. Agarwal, J.D. Reveille, S. Assassi, M. Mayes, Y. Deng, J.P. Drenth, J. de Graaf, M. den Heijer, C.G. Kallenberg, M. Bijl, A. Loof, W.B. van den Berg, L.A. Joosten, V. Smith, F. de Keyser, R. Scorza, C. Lunardi, P.L. van Riel, M. Vonk, W. van Heerde, S. Meller, B. Homey, L. Beretta, M. Roest, M. Trojanowska, R. Lafyatis, and T.R. Radstake Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis N. Engl. J. Med. 370 2014 433 443
59. K. Palumbo-Zerr, P. Zerr, A. Distler, J. Fliehr, R. Mancuso, J. Huang, D. Mielenz, M. Tomcik, B.G. Furnrohr, C. Scholtysek, C. Dees, C. Beyer, G. Kronke, D. Metzger, O. Distler, G. Schett, and J.H. Distler Orphan nuclear receptor NR4A1 regulates transforming growth factor-beta signaling and fibrosis Nat. Med. 21 2015 150 158
60. C. Beyer, J. Huang, J. Beer, Y. Zhang, K. Palumbo-Zerr, P. Zerr, A. Distler, C. Dees, C. Maier, L. Munoz, G. Kronke, S. Uderhardt, O. Distler, S. Jones, S. Rose-John, T. Oravecz, G. Schett, and J.H. Distler Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages Ann. Rheum. Dis. 74 2015 1317 1324
61. C. Beyer, A. Skapenko, A. Distler, C. Dees, H. Reichert, L. Munoz, J. Leipe, H. Schulze-Koops, O. Distler, G. Schett, and J.H. Distler Activation of pregnane X receptor inhibits experimental dermal fibrosis Ann. Rheum. Dis. 72 2013 621 625
62. J.E. Milam, V.G. Keshamouni, S.H. Phan, B. Hu, S.R. Gangireddy, C.M. Hogaboam, T.J. Standiford, V.J. Thannickal, and R.C. Reddy PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis Am. J. Physiol. Lung Cell. Mol. Physiol. 294 2008 L891 L901
63. Q. Wang, W. Usinger, B. Nichols, J. Gray, L. Xu, T.W. Seeley, M. Brenner, G. Guo, W. Zhang, N. Oliver, A. Lin, and D. Yeowell Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease Fibrogenesis Tissue Repair 4 2011 4
64. K.E. Lipson, C. Wong, Y. Teng, and S. Spong CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis Fibrogenesis Tissue Repair 5 2012 S24
65. A.M. Tager, P. LaCamera, B.S. Shea, G.S. Campanella, M. Selman, Z. Zhao, V. Polosukhin, J. Wain, B.A. Karimi-Shah, N.D. Kim, W.K. Hart, A. Pardo, T.S. Blackwell, Y. Xu, J. Chun, and A.D. Luster The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak Nat. Med. 14 2008 45 54
66. A. Akhmetshina, K. Palumbo, C. Dees, C. Bergmann, P. Venalis, P. Zerr, A. Horn, T. Kireva, C. Beyer, J. Zwerina, H. Schneider, A. Sadowski, M.O. Riener, O.A. MacDougald, O. Distler, G. Schett, and J.H. Distler Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis Nat. Commun. 3 2012 735
67. W. He, C. Dai, Y. Li, G. Zeng, S.P. Monga, and Y. Liu Wnt/beta-catenin signaling promotes renal interstitial fibrosis J. Am. Soc. Nephrol. 20 2009 765 776
68. K. Kobayashi, M. Luo, Y. Zhang, D.C. Wilkes, G. Ge, T. Grieskamp, C. Yamada, T.C. Liu, G. Huang, C.T. Basson, A. Kispert, D.S. Greenspan, and T.N. Sato Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction Nat. Cell Biol. 11 2009 46 55
69. M. Konigshoff, M. Kramer, N. Balsara, J. Wilhelm, O.V. Amarie, A. Jahn, F. Rose, L. Fink, W. Seeger, L. Schaefer, A. Gunther, and O. Eickelberg WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis J. Clin. Invest. 119 2009 772 787
70. A.P. Lam, A.S. Flozak, S. Russell, J. Wei, M. Jain, G.M. Mutlu, G.R. Budinger, C.A. Feghali-Bostwick, J. Varga, and C.J. Gottardi Nuclear beta-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation Am. J. Respir. Cell Mol. Biol. 45 2011 915 922
71. M. Sato Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids Acta Derm. Venereol. 86 2006 300 307
72. K. Surendran, S. Schiavi, and K.A. Hruska Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis J. Am. Soc. Nephrol. 16 2005 2373 2384
73. A. Ulsamer, Y. Wei, K.K. Kim, K. Tan, S. Wheeler, Y. Xi, R.S. Thies, and H.A. Chapman Axin pathway activity regulates in vivo pY654-beta-catenin accumulation and pulmonary fibrosis J. Biol. Chem. 287 2012 5164 5172
74. J. Wei, F. Fang, A.P. Lam, J.L. Sargent, E. Hamburg, M.E. Hinchcliff, C.J. Gottardi, R. Atit, M.L. Whitfield, and J. Varga Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells Arthritis Rheum. 64 2012 2734 2745
75. J. Wei, D. Melichian, K. Komura, M. Hinchcliff, A.P. Lam, R. Lafyatis, C.J. Gottardi, O.A. MacDougald, and J. Varga Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum. 63 2011 1707 1717
76. R. Nusse Wnt signaling Cold Spring Harb. Perspect. Biol. 4 2012
77. J. Bayle, J. Fitch, K. Jacobsen, R. Kumar, R. Lafyatis, and R. Lemaire Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis J. Invest. Dermatol. 128 2008 871 881
78. C. Bergmann, A. Akhmetshina, C. Dees, K. Palumbo, P. Zerr, C. Beyer, J. Zwerina, O. Distler, G. Schett, and J.H. Distler Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway Ann. Rheum. Dis. 70 2011 2191 2198
79. C. Beyer, A. Schramm, A. Akhmetshina, C. Dees, T. Kireva, K. Gelse, S. Sonnylal, B. de Crombrugghe, M.M. Taketo, O. Distler, G. Schett, and J.H. Distler Beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis Ann. Rheum. Dis. 71 2012 761 767
80. E.J. Hamburg, and R.P. Atit Sustained beta-catenin activity in dermal fibroblasts is sufficient for skin fibrosis J. Invest. Dermatol. 132 2012 2469 2472
81. P. Polakis Drugging Wnt signalling in cancer EMBO J. 31 2012 2737 2746
82. A. Distler, L. Deloch, J. Huang, C. Dees, N.Y. Lin, K. Palumbo-Zerr, C. Beyer, A. Weidemann, O. Distler, G. Schett, and J.H. Distler Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling Ann. Rheum. Dis. 72 2013 1575 1580
83. C. Beyer, H. Reichert, H. Akan, T. Mallano, A. Schramm, C. Dees, K. Palumbo-Zerr, N.Y. Lin, A. Distler, K. Gelse, J. Varga, O. Distler, G. Schett, and J.H. Distler Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis Ann. Rheum. Dis. 72 2013 1255 1258
84. C. Dees, I. Schlottmann, R. Funke, A. Distler, K. Palumbo-Zerr, P. Zerr, N.Y. Lin, C. Beyer, O. Distler, G. Schett, and J.H. Distler The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis Ann. Rheum. Dis. 73 2014 1232 1239
85. H. Kantarjian, J.P. Issa, C.S. Rosenfeld, J.M. Bennett, M. Albitar, J. DiPersio, V. Klimek, J. Slack, C. de Castro, F. Ravandi, R. Helmer 3rd, L. Shen, S.D. Nimer, R. Leavitt, A. Raza, and H. Saba Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 2006 1794 1803
86. H. Kantarjian, Y. Oki, G. Garcia-Manero, X. Huang, S. O'Brien, J. Cortes, S. Faderl, C. Bueso-Ramos, F. Ravandi, Z. Estrov, A. Ferrajoli, W. Wierda, J. Shan, J. Davis, F. Giles, H.I. Saba, and J.P. Issa Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 2007 52 57
87. Y. Oki, and J.P. Issa Review: recent clinical trials in epigenetic therapy Rev. Recent Clin. Trials 1 2006 169 182
88. P.W. Ingham, Y. Nakano, and C. Seger Mechanisms and functions of Hedgehog signalling across the metazoa Nat. Rev. Genet. 12 2011 393 406
89. A. Horn, T. Kireva, K. Palumbo-Zerr, C. Dees, M. Tomcik, C. Cordazzo, P. Zerr, A. Akhmetshina, M. Ruat, O. Distler, C. Beyer, G. Schett, and J.H. Distler Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis Ann. Rheum. Dis. 71 2012 785 789
90. A. Horn, K. Palumbo, C. Cordazzo, C. Dees, A. Akhmetshina, M. Tomcik, P. Zerr, J. Avouac, J. Gusinde, J. Zwerina, H. Roudaut, E. Traiffort, M. Ruat, O. Distler, G. Schett, and J.H. Distler Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis Arthritis Rheum. 64 2012 2724 2733
91. P. Zerr, K. Palumbo-Zerr, A. Distler, M. Tomcik, S. Vollath, L.E. Munoz, C. Beyer, C. Dees, F. Egberts, I. Tinazzi, F. Del Galdo, O. Distler, G. Schett, B.M. Spriewald, and J.H. Distler Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease Blood 120 2012 2909 2917
92. M.E. Fortini Notch signaling: the core pathway and its posttranslational regulation Dev. Cell 16 2009 633 647
93. B. Bielesz, Y. Sirin, H. Si, T. Niranjan, A. Gruenwald, S. Ahn, H. Kato, J. Pullman, M. Gessler, V.H. Haase, and K. Susztak Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans J. Clin. Invest. 120 2010 4040 4054
94. C. Dees, M. Tomcik, P. Zerr, A. Akhmetshina, A. Horn, K. Palumbo, C. Beyer, J. Zwerina, O. Distler, G. Schett, and J.H. Distler Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis Ann. Rheum. Dis. 70 2011 1304 1310
95. N. Kavian, A. Servettaz, C. Mongaret, A. Wang, C. Nicco, C. Chereau, P. Grange, V. Vuiblet, P. Birembaut, M.D. Diebold, B. Weill, N. Dupin, and F. Batteux Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model Arthritis Rheum. 62 2010 3477 3487
96. C. Dees, P. Zerr, M. Tomcik, C. Beyer, A. Horn, A. Akhmetshina, K. Palumbo, N. Reich, J. Zwerina, M. Sticherling, M.P. Mattson, O. Distler, G. Schett, and J.H. Distler Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis Arthritis Rheum. 63 2011 1396 1404
97. E.R. Andersson, and U. Lendahl Therapeutic modulation of Notch signalling - are we there yet? Nat. Rev. Drug Discov. 13 2014 357 378
98. C. Groth, and M.E. Fortini Therapeutic approaches to modulating Notch signaling: current challenges and future prospects Semin. Cell Dev. Biol. 23 2012 465 472
99. G.H. Searfoss, W.H. Jordan, D.O. Calligaro, E.J. Galbreath, L.M. Schirtzinger, B.R. Berridge, H. Gao, M.A. Higgins, P.C. May, and T.P. Ryan Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor J. Biol. Chem. 278 2003 46107 46116
100. J.H. van Es, M.E. van Gijn, O. Riccio, M. van den Born, M. Vooijs, H. Begthel, M. Cozijnsen, S. Robine, D.J. Winton, F. Radtke, and H. Clevers Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells Nature 435 2005 959 963
101. M. Trojanowska Cellular and molecular aspects of vascular dysfunction in systemic sclerosis Nat. Rev. Rheumatol. 6 2010 453 460
102. B. Maurer, J. Stanczyk, A. Jungel, A. Akhmetshina, M. Trenkmann, M. Brock, O. Kowal-Bielecka, R.E. Gay, B.A. Michel, J.H. Distler, S. Gay, and O. Distler MicroRNA-29, a key regulator of collagen expression in systemic sclerosis Arthritis Rheum. 62 2010 1733 1743